30/07/2024
🚨 Big Announcement! 🚨
Cystic Fibrosis Australia, your Peak National Body, is thrilled to share that Trikafta will now be available on the Pharmaceutical Benefits Scheme (PBS) for children aged 2+ with at least one F508del mutation, starting Thursday 1st August 2024. This expansion will benefit approximately 290 children, including 100 children gaining access to a modulator for the first time. 🎉
Your voices have been heard, and your advocacy has made a significant impact. We extend our heartfelt thanks to everyone who wrote submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) and shared their stories. This milestone wouldn’t be possible without you.
Heath, a 4-year-old living with CF, and his family have been waiting for this moment. Now, he will have access to Trikafta before he starts school, thanks to our collective efforts. His story, like many others, underscores the importance of our ongoing advocacy.
Special thanks to our Federation Members, the Health Department, Vertex Pharmaceuticals, and everyone involved in making this expansion possible. Together, we are driving real change and transforming lives.
👉 Click the link to read the full communique from our CEO, Jo Armstrong: https://mailchi.mp/cfa.org.au/your-voice-matters-6412249
Mark Butler MP